Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B

New England Journal of Medicine

Volumn 354, Issue 10, 2006, Pages 1011-1020

  Lai, Ching Lung ^a   Shouval, Daniel ^b   Lok, Anna S ^c   Chang, Ting Tsung ^d   Cheinquer, Hugo ^e   Goodman, Zachary ^f   DeHertogh, Deborah ^g   Wilber, Richard ^h   Zink, Richard C ^h   Cross, Anne ^h   Colonno, Richard ^h   Fernandes, Lori ^h  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^g UNIVERSITY OF CONNECTICUT   (United States)

^h BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; BACKACHE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; EVALUATION; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLUENZA; INSOMNIA; KNODELL NECROINFLAMMATORY SCORE; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; TREATMENT OUTCOME;

EID: 33644822860     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa051287     Document Type: Article

References (35)

1. Hepatitis B: fact sheet WHO/204. Geneva: World Health Organization, October 2000. (Accessed February 10, 2006, at http: //www.who.int/mediacentre/ factsheets/ fs204/en.)
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
3. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995;1:7-36.
4. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
5. Funk ML, Rosenberg DM, Lok ASF. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
6. Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000;31:763-8.
7. Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002;186:1335-8.
8. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15.
9. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003;98:2261-7.
10. Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment Pharmacol Ther 2004;19:25-37.
11. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 2002;36:263-70.
12. Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39:Suppl 1:S50-S58.
13. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003; 38:Suppl 1:S90-S103.
14. [Erratum, J Hepatol 2003;38:876.]
15. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005;42:173-9.
16. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
17. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91.
18. Lok ASF, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-61.
19. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
20. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;39: Suppl 1:S3-S25.
21. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15:825-41.
22. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8.
23. Chang T-T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
24. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
25. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507.
26. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
27. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53.
28. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAgnegative chronic hepatitis B. Semin Liver Dis 2003;23:81-8.
29. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
30. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
31. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
32. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002;66:435-51.
33. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
34. [Erratum, N Engl J Med 2003;348:1192.]
35. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005;42:Suppl 2:17. abstract.